QMID Standardizes Liquid Cannabis Administration
Edited by Mursal Rahman — October 4, 2026 — Business
This article was written with the assistance of AI.
References: prnewswire
Curaleaf International and Jupiter Research are expanding standardized medical cannabis delivery with QMID, a reusable inhalation device designed for prescribed liquid cannabis extracts. Registered as a Class IIb medical device in Australia, QMID provides controlled aerosolization intended to support consistent dosing. The compact system works exclusively with approved cartridges and follows its earlier certification under the European Medical Device Regulation. It has also been listed in New Zealand, extending its international availability.
The regulated format gives clinicians and patients an alternative to inhalation hardware supplied outside established medical device frameworks. For Curaleaf, QMID creates an opportunity to expand beyond cannabis medicines into the technology used to administer them, strengthening its role across the treatment pathway. Regulatory clearance in multiple markets may also support further geographic expansion while providing healthcare professionals with a standardized delivery system designed around prescribed cannabis-based medicines.
Image Credit: Curaleaf International
The regulated format gives clinicians and patients an alternative to inhalation hardware supplied outside established medical device frameworks. For Curaleaf, QMID creates an opportunity to expand beyond cannabis medicines into the technology used to administer them, strengthening its role across the treatment pathway. Regulatory clearance in multiple markets may also support further geographic expansion while providing healthcare professionals with a standardized delivery system designed around prescribed cannabis-based medicines.
Image Credit: Curaleaf International
Trend Themes
-
Standardized Cannabis Delivery — Medical-grade inhalation systems create room for consistent dosing models that separate prescribed cannabis therapies from informal consumption hardware.
-
Regulated Vaporization Devices — Certified aerosol technologies can reshape cannabis treatment by aligning device design, cartridge control, and clinical oversight within medical-device frameworks.
-
Closed-cartridge Therapeutics — Exclusive cartridge ecosystems introduce platform-based opportunities for pharmaceutical cannabis brands to manage quality, compliance, and recurring patient use.
Industry Implications
-
Medical Cannabis — The sector is moving toward prescription-aligned administration formats that support clinician confidence and differentiated therapeutic positioning.
-
Medical Devices — Reusable inhalers for liquid extracts expand device innovation into plant-derived therapies where precision, safety, and approvals influence adoption.
-
Pharmaceutical Technology — Integrated drug-device systems are becoming a strategic bridge between cannabinoid formulations and regulated healthcare delivery channels.
5.2
Score
Popularity
Activity
Freshness
